AMT Medical Secures $25M Series B Funding to Advance Minimally Invasive Elana Coronary Bypass System

Apr 23, 2025 11:18 CST Updated 11:18

AMT Medical

Coronary Artery Bypass Technology Researcher

Award Selection Postponed! Cardiovascular Companies Act Fast! First Global Cardiovascular Conference!

Heart Future

Recently,AMT MedicalAnnounced the completion of Series B financing$25 million(Contract180 million RMB), to support itsElana Coronary Bypass SystemSubsequent research and development, regulatory applications, and other tasks.

The Elana system is designed toReplace traditional open-chest bypass surgery, which is expected to be compatible with surgical robots, enabling robot-assisted minimally invasive surgeries.

New investors Invest-NL and the European Innovation Council (EIC), along with existing investors such as Oost NL, participated in this round of financing. The company is expected to obtain CE certification by 2026.

# Product Details

Research and Development Background

In traditional coronary artery bypass surgery, surgeons typically use venous vessels (such as the great saphenous vein) as graft materials. This is because venous vessels are easy to obtain and relatively simple to handle. However, venous vessels have some limitations,For example, poor long-term patency may lead to postoperative vascular restenosis.
Moreover, traditional coronary artery bypass surgery usually requires open-chest surgery, which...OverA larger chest incision (typically a median sternotomy) to expose the heart. This surgical method is more invasive and has a longer recovery time.
In addition, in traditional coronary artery bypass surgery, for the convenience of surgical operation,CommonIt is necessary to stop the heart from beating and use a cardiopulmonary bypass machine (heart-lung machine) to maintain blood circulation.However, cardiopulmonary bypass may bring some complications, such as stroke, bleeding, and renal insufficiency.

Product Features

Arterial Bypass:The Elana system allows surgeons to use arterial vessels (such as the internal thoracic artery) for bypass. Arterial vessels have more advantages than venous vessels because they offer better hemodynamic performance, higher long-term patency, and can more effectively improve coronary blood flow.

Minimally Invasive Surgery:The Elana system adopts minimally invasive surgical techniques, allowing surgeons toThrough a small incision into the chest cavityPerform surgery,Reduced surgical trauma, alleviated postoperative pain, and shortened hospital stays and recovery time.

Off-pump surgery:The Elana system allows surgeons to perform operations without stopping the heartbeat.The extracorporeal circulation machine is not required during the operation., thereby eliminating the risk of stroke and other complications associated with extracorporeal circulation. Off-pump surgery is more consistent with physiological conditions and reduces stress responses in patients.
Sutureless Anastomosis Technique:The Elana system uses sutureless anastomosis technology,Using proprietary clips and excimer laser to connect blood vessels without manual suturing, which not only improves the precision and repeatability of the surgery, but also reduces the operation time and the risk of complications.
Standard Operating Procedure:No matter which surgeon uses the system, it can complete the vascular connection in the same way, ensuring consistency in surgical quality, making the system easier to be widely promoted and applied.

# Research Progress

Previously, the company reported positive results from its first milestone, the First-in-Human (FIH) CE Mark trial.

First-in-Human (FIH) SAFE-CAB Trial Phase I Demonstrates Encouraging Results Involving 10 Subjects. In the first phase of SAFE-CAB, Elana The cardiac bypass system has been proven to be safe and feasible in humans, with no major adverse cardiovascular events (MACE) reported among all trial participants at 30 days post-operation.

AMT Medical Also receivedSignificant support from the European Innovation Council (EIC) Accelerator and the Netherlands Enterprise Agency Innovation Credit has resulted in millions of euros.Yuan's appropriation.

AMT Medical Another trial has been prepared and is now expanding to 75 subjects, with the ultimate goal of obtaining commercial use approval in Europe. Additionally, the company is now in final discussions with the U.S. FDA to initiate an early feasibility study for the system in the United States. ElanaCerebral vascular bypass surgery has saved the lives of up to a thousand patients in Europe, the United States, and Canada.

# AboutAMT Medical

AMT MedicalIs an innovative medical technology company, through itsElanaCardiac Bypass System, is driving a transformation in the field of cardiovascular surgery. The system not only enhances the safety and effectiveness of surgeries but also reduces costs and shortens recovery time, bringing significant benefits to patients. As clinical trials progress and regulatory approvals are gradually obtained, AMT Medical is expected to play a major role in the global cardiovascular care sector.

^{Meeting Notice:}

^{The First Global Cardiovascular Conference (Global Cardiovascular Conference 2025) and Innovation Awards CeremonyTo be held in May this year. The award selection method is now announced. Companies are welcome to register for participation!}

^{Register Now! The First Global Cardiovascular Conference and Awards Ceremony}